Ms. Rama Kirloskar currently serves as Joint Managing Director of Kirloskar Brothers Limited and also Managing Director of Kirloskar Ebara Pumps Limited (KEPL), a joint venture between Ebara Corporation, Japan and Kirloskar Brothers Limited, parent company of the 130-year-old Kirloskar Group. Previously, she was General Manager and Head of the Product Portfolio Management at Kirloskar Brothers Limited, where she was responsible for driving the Go-to-market strategy, product value management and restructuring for the mass production business; material grade rationalization and streamlining for the foundry business and product rationalization for the made-to-order business.
She holds a double major in Mathematics and Biology from Bryn Mawr College, USA. After graduation, she went on to work at Polaris Partners, a multi-stage venture capital firm that principally invests in technology, healthcare and consumer products, headquartered at Boston, MA, USA. Subsequently, she worked at the Koch Institute at Massachusetts Institute of Technology (MIT), USA. Her research led her and the team to begin working with Visterra Inc., an MIT biotechnology start-up company that currently uses its proprietary platform to design therapeutics for infectious diseases.
She is one of the authors of a recent publication in the journal Cell (Robinson et al.,2015,Cell 162,1-12,doi:10.1016/j.cell.2015.06.057), in the paper titled Structure-Guided Design of an Anti-Dengue Antibody Directed to a Non-Immunodominant Epitope.
She is also on the Board of Kirloskar Brothers Limited and Prakar Investments Private Limited.
She holds a double major in Mathematics and Biology from Bryn Mawr College, USA. After graduation, she went on to work at Polaris Partners, a multi-stage venture capital firm that principally invests in technology, healthcare and consumer products, headquartered at Boston, MA, USA. Subsequently, she worked at the Koch Institute at Massachusetts Institute of Technology (MIT), USA. Her research led her and the team to begin working with Visterra Inc., an MIT biotechnology start-up company that currently uses its proprietary platform to design therapeutics for infectious diseases.
She is one of the authors of a recent publication in the journal Cell (Robinson et al.,2015,Cell 162,1-12,doi:10.1016/j.cell.2015.06.057), in the paper titled Structure-Guided Design of an Anti-Dengue Antibody Directed to a Non-Immunodominant Epitope.
She is also on the Board of Kirloskar Brothers Limited and Prakar Investments Private Limited.
